Clinical Study on Oral Nemonoxacin Malate Capsules

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and tolerability of nemonoxacin in healthy Chinese volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion

NCT01529957

Healthy

COMPLETED PHASE1

Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride

NCT01944774

Pneumonia

COMPLETED PHASE2

A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP

NCT02205112

Community-acquired Pneumonia

COMPLETED PHASE3

Evaluate Pathogens and Immunity to Acute Otitis Media in Healthy Children.

NCT02591563

Nasopharyngeal Colonization and Acute Otitis Media

ACTIVE_NOT_RECRUITING

Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

NCT01435525

Gastric Ulcer Duodenal Ulcer Gastric Mucosa-associated Lymphoid Tissue (MALT) +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Single dose study: evaluate safety and tolerability of oral nemonoxacin 125 mg, 250mg, 500mg, 750mg, and 1000mg.

Multiple dose study: evaluate PK profile of oral doses of 500mg or 750mg nemo after consecutive 10 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

oral once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TG-873870

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males and females, aged between 18 and 45 during screening
* Male volunteers who are capable of taking double-barrier contraception measures during the test (spermicide gel plus condom, for instance) until the end of the clinical study and do not cause their spouses to conceive within three months after the last administration of the medication; if the subjects are females, they shall not become pregnant during the test and within three months after the study
* No use of tobacco or nicotine product within 3 months prior to this study
* BMI 19-25
* Willing to abstain from coffee and any caffeine drink during the study
* Voluntarily sign the informed consent

Exclusion Criteria

* History of diabetes, or cardiovascular, hepatic or renal disease
* Active digestive disease (e.g. diarrhea)
* Central nervous disease or psychiatric disorders
* Had surgery or trauma within 6 months prior to this study
* Alcohol or drug abuse
* HIV, HBV or HCV positive
* Used any prescribed drug (including traditional chinese medicine) within 14 days prior to the study
* Donated 400ml of blood or plasma within 3 months prior to this study
* Have an abnormal laboratory examination value that exceeds the normal range by 10%
* Drug allergies
* Have cardiac disorders or have a family history of cardiac disorders
* Have abnormal 12-lead ECG during screening
* Pregnant or lactating
* Participated in any study within 3 months prior to this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes